



Press release

Stockholm, 3 June 2020

Bactiguard initiates collaboration with online pharmacy Apotea on sales of Hydrocyn® aqua

Bactiguard initiates collaboration with the online pharmacy Apotea on sales of Hydrocyn® aqua (Hydrocyn) to consumers in the Swedish market. Recent tests confirm that Hydrocyn is the first disinfectant on the Swedish market with documented effect on the new Corona virus causing COVID-19. Sales via Apotea will commence on 5 June.

“We are pleased that Bactiguard initially has chosen to work exclusively with Apotea for the launch of Hydrocyn to consumers,” says Per Svärdson, Apotea's CEO.

“We are seeing a continued high demand for disinfectants. That we can now offer advanced disinfection, which has a proven effect against the coronavirus, is important in the fight against the spread of covid-19. Apotea is Sweden's largest online pharmacy with deliveries all over Sweden, every day of the week,” Per Svärdson continues.

“The spread of the covid-19 pandemic has been much greater and more severe than anyone could imagine. The lack of effective remedies and vaccine increases the need for prevention. Hand disinfection is one of the most important measures to prevent being infected or spreading the virus to others. Therefore, we are very pleased that we are now able to offer Hydrocyn, which effectively kills the Corona virus to private individuals in collaboration with Apotea,” says Cecilia Edström, CEO of Bactiguard.

Bactiguard launched Hydrocyn in the Swedish market in mid-March and received customer orders, including from the Police Authority, in the first days after the launch, at a total value of just over SEK 20 million. Initially, customers with critical societal functions were given priority.

On June 2, the results of tests conducted by the Swedish National Veterinary Institute (SVA) on the new coronavirus (SARS-CoV-2) that causes covid-19 were published. The tests show that 99.9% of the virus particles were killed after exposure to Hydrocyn ([link to press release](#)).

From Friday, June 5, private individuals will also be able to order Hydrocyn through the Swedish online pharmacy Apotea.

About Hydrocyn® aqua

Hydrocyn® aqua is an advanced disinfectant that is pH-neutral and water-based and can be used as a disinfectant solution for, for example, skin and surfaces. Unlike alcohol-based disinfectants,



Hydrocyn® aqua is not irritating, toxic or harmful to the body. It is also not flammable. The active substance (HOCl) is a natural part of the human immune system. The product is CE marked (approved in the EU), registered by the US FDA and approved by the Swedish Chemicals Agency.

Film about Hydrocyn: <https://www.hydrocyn.se/sv/press/#video>

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-06-03, at. 11.05.

For further information, please contact:

Cecilia Edström, CEO, e-mail cecilia.edstrom@bactiguard.se, phone: +46 8 440 58 80

Christian Huber, procurement manager Apotea, e-mail christian.huber@apotea.se
mobile: +46 701 981 016



Pär Svårdson, CEO Apotea



Cecilia Edström, CEO Bactiguard



Bactiguard Hydrocyn® aqua

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through license agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our license partner BD, urinary catheters with Bactiguard's coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.

Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.

Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives at www.bactiguard.com